ELICIO THERAPEUTICS INC. - COMMON STOCK

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

29 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

18 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

05 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

25 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

17 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

16 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

11 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

09 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

22 Dec 2023 09:00:32 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

09 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

03 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

06 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

03 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

02 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Completion of Merger with Angion Biomedica

01 Jun 2023 16:04:00 By Nasdaq GlobeNewswire